{"word_count": 223, "character_count": 1617}
 Auteur : rédaction de Kyodo News.  Production :  The Japan Times.  Diffusion : site de The Japan Times.Date : 20 mai 2020.The lack of results have raised doubts about its approval by the end of this monthAvigan, a candidate drug for treating COVID-19, has not shown apparent  efficacy in treating the respiratory disease in clinical trials so far,  raising doubts about its approval by the end of this month as sought by  the government, sources familiar with the matter said Tuesday. Source : Kyodo, « Drug Avigan that was pushed by Abe falls short in COVID-19 trials », The Japan Times, 20/05/2020. URL : https://www.japantimes.co.jp/news/2020/05/20/national/science-health/avigan-coronavirus-results/#.XsUG6sA69PY (consulté le 20/05/2020)  Abe touts Avigan as COVID-19 treatment despite experts urging cautionAuteur : rédaction de Kyodo News.Production : Kyodo News / 共同通信社, agence de presse au Japon depuis 1945.Diffusion : site de Kyodo News Plus (en anglais).Date : 23 avril 2020.Prime Minister Shinzo Abe has enthusiastically promoted  anti-influenza drug Avigan as a possible game-changer in the war against  the coronavirus, but medical experts have called for caution, citing  its side effects and yet unproven efficacy.Source : Kyodo News,  « Abe touts Avigan as COVID-19 treatment despite experts urging caution » , Kyodo News Plus, 23/04/2020. URL :https://english.kyodonews.net/news/2020/04/fdbe6ef2fdfa-focus-abe-touts-avigan-as-covid-19-treatment-despite-experts-urging-caution.html (consulté le 23/04/2020)Photo  « à la une » : The anti-influenza drug Avigan © FUJIFILM HOLDINGS CORP. / VIA KYODO.  